Real-world results for empagliflozin published
Patients with HbA1c above 53mmol/mol show most improvement, say researchers
Real-world use of empagliflozin by people with type 2 diabetes gives similar reductions in HbA1c to that seen in clinical trials, Danish researchers say.
The investigators used Northern Denmark healthcare data from 2009-18 to identify new users of the SGLT-2 inhibitor and compared their characteristics with those of eligibility criteria in the four clinical trials of the drug.
